Why the study?
Does intravenous nadolol alter cardiac electrophysiologic parameters?
Does intravenous nadolol alter cardiac electrophysiologic parameters?
Intravenous nadolol acutely slows atrioventricular nodal conduction and increases refractoriness, consistent with the known electrophysiologic effects of other beta-blockers.
Acute AV nodal slowing with IV nadolol may aid rate control; leaves open comparative efficacy versus other beta-blockers in arrhythmia trials.
The acute effects of intravenous nadolol (0.01 and 0.02 mg/kg) on cardiac electrophysiologic parameters were assessed with His bundle recording and programmed atrial stimulation. The higher dose of nadolol reduced resting heart rate (71 vs. 65 beats/min, P less than 0.02), and the degree of slowing was related to the initial heart rate (r = -0.68, P less than 0.05). Atrioventricular conduction time as defined by the paced A-H interval, rose by 12 msec (P less than 0.001) after nadolol (0.02 mg/kg) administration. Atrial refractoriness increased (by 10 msec, P less than 0.02) only at the higher dose level with nadolol. At both dose levels, atrioventricular nodal effective and functional refractory periods were increased (P less than 0.02) by a mean of 45 and 21 msec, respectively, suggesting greater sensitivity of atrioventricular nodal refractoriness to beta-adrenergic blockade. Nadolol's effects were generally similar to those of previously reported studies with other beta-adrenergic blockers. These data suggest that nadolol slows conduction through the atrioventricular node and increases atrial and atrioventricular nodal refractoriness.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: